Rimke BijkerJun Yong ChoiRossana DitangcoSasisopin KiertiburanakulMan Po LeeSarawut SiwamogsathamSanjay PujariJeremy RossChi Yuen WongWing Wai WongEvy YunihastutiMatthew LawUniversity of New South Wales (UNSW) AustraliaYonsei University College of MedicineGokilaMahidol UniversityQueen Elizabeth Hospital Hong KongKing Chulalongkorn Memorial Hospital, Faculty of Medicine Chulalongkorn UniversityChulalongkorn UniversityInstitute of Infectious DiseasesTREAT AsiaVeterans General Hospital-TaipeiUniversity of Indonesia, RSUPN Dr. Cipto Mangunkusumo2018-12-212019-03-142018-12-212019-03-142017-08-01Open AIDS Journal. Vol.11, (2017), 52-66187461362-s2.0-85030779657https://repository.li.mahidol.ac.th/handle/20.500.14594/42802© 2017 Bijker et al. Introduction: Cardiovascular diseases (CVD) are becoming more prevalent in HIV-infected populations as they age largely due to improved treatment outcomes. Assessment of CVD risk and CVD risk factors in HIV-positive populations has focused on high income settings, while there are limited studies evaluating CVD in HIV-positive populations in the Asian region. Materials and Methods: We provided an overview of the prevalence and incidence of CVD and its risk factors in adult HIV-positive populations, and of the strategies currently in place for CVD management in the Asian region. Results: Studies from the Asian region showed that CVD and CVD risk factors, such as dyslipidaemia, elevated blood glucose, obesity and smoking, are highly prevalent in HIV-positive populations. A number of studies suggested that HIV infection and antiretroviral therapy may contribute to increased CVD risk. National HIV treatment guidelines provide some directions regarding CVD risk prevention and management in the HIV-infected population, however, they are limited in number and scope. Conclusion: Development and consolidation of guidelines for integrated CVD and HIV care are essential to control the burden of CVD in HIVpositive populations. To inform guidelines, policies and practice in the Asian region, research should focus on exploring appropriate CVD risk screening strategies and estimating current and future CVD mortality and morbidity rates.Mahidol UniversityImmunology and MicrobiologyReviewSCOPUS10.2174/1874613601711010052